FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients with prior failure on therapy with non-pegylated interferon or pegylated interferon and negative at week 12, the sustained response rates were 59 % and 50 %, respectively.
Croatian: Stope trajnog odgovora ostvarilo je 59 % bolesnika prethodno neuspješno liječenih nepegiliranim intereferonom te 50 % bolesnika prethodno neuspješno liječenih pegiliranim intereferonom koji su imali negativan nalaz u 12. tjednu.
English: Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established.
Croatian: Ako je već uveden kombinirani antiretrovirusni režim liječenja, mora se razmotriti zamjenu zidovudina drugim lijekom.
English: p value b
Croatian: pvrijednost b
English: Genotype 1* By Week 4*** (n= 950) HCV-RNA negative
Croatian: 4. tjedna*** (n= 950) HCV-RNK negativna HCV-RNK negativna ili virusno opterećenje manje za ≥1 log
English: This medicine does not affect your ability to drive or use machines; however, interferon alfa-2b may affect your ability to drive or use machines.
Croatian: Međutim, inteferon alfa-2b može utjecati na sposobnost upravljanja vozilima ili strojevima.
English: Overall Responsea (n = 118) Genotype 1 (n = 92)
Croatian: (n = 118)
English: Safety and effectiveness of Ribavirin Mylan with pegylated or other forms of interferon (i.e. not alfa-2b) in these patients have not been evaluated.
Croatian: U tih bolesnika nije provedena procjena sigurnosti i učinkovitosti lijeka Ribavirin Mylan s pegiliranim ili drugim oblicima interferona (tj. interferonima koji ne pripadaju skupini alfa-2b).
English: In a separate trial, 224 patients with genotype 2 or 3 received peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with ribavirin 800 mg-1,400 mg p.o. for 6 months
Croatian: U odvojenom su ispitivanju 224 bolesnika inficirana virusom genotipa 2 ili 3 tijekom 6 mjeseci primala peginterferon alfa-2b supkutano u dozi od 1,5 mikrograma/kg jedanput na tjedan, u kombinaciji s ribavirinom u peroralnoj dozi od 800 mg - 1400 mg (na temelju tjelesne težine; samo su tri bolesnika koja su težila > 105 kg primila dozu od 1400 mg) (Tablica 8).
English: Contact your doctor immediately if you notice any of the following side effects occurring during combination treatment with an alpha interferon product:
Croatian: Ako se za vrijeme uzimanja kombiniranog liječenja s alfa inteferonom pojavi neka od sljedećih nuspojava, odmah se javite svom liječniku:
English: Mylan is by an additional 200 mg/day.
Croatian: Ako je potrebno, drugo smanjenje doze je za dodatnih 200 mg/dan.
English: HCV 2 ≤ 600,000 IU/ml > 600,000 IU/mL 100% (22/22) HCV 3 ≤ 600,000 IU/ml > 600,000 IU/ml
Croatian: Svi ispitanici HCV 2 ≤ 600 000 IU/ml > 600 000 IU/ml HCV 3 ≤ 600 000 IU/ml > 600 000 IU/ml * Za sve ispitanike s nemjerljivom razinom HCV-RNK u 12. tjednu praćenja i nedostatkom podataka u 24. tjednu praćenja smatralo se da imaju trajan odgovor.
English: Interferon alfa-2b 3 MIU/m2 3 times a week (n = 54)
Croatian: Interferon alfa-2b 3 MIU/m
English: Fatigue, rigors, pyrexia, influenza-like illness, asthenia, malaise, irritability
Croatian: umor, tresavica, pireksija, bolest nalik gripi, astenija, malaksalost, iritabilnost često:
English: Mylan AB Tel: +46 855 522 750
Croatian: Tel: +46 855 522 750
English: Lower respiratory tract infection
Croatian: Početno virusno opterećenje
English: Combination therapy with alpha interferons should be discontinued in patients who develop new or worsening ophthalmologic disorders.
Croatian: U bolesnika u kojih se razviju novi ili pogoršaju postojeći očni poremećaji mora se prekinuti kombinirano liječenje s alfa interferonima.
English: Very commonly reported side effects (may affect more than 1 in 10 people): decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils (that make you more susceptible to different infections), decrease in thyroid gland activity (which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms), feeling depressed or irritable, feeling sick to stomach, feeling unwell, mood swings, tired feeling, trouble falling asleep or staying asleep, virus infection, weakness, diarrhoea, dizziness, fever, flu-like symptoms, headache, loss of or increase in appetite, loss of weight, decrease in the rate of growth (height and weight), pain on right side of ribs, pharyngitis (sore throat), shaking chills, stomach pain, vomiting, dry skin, hair loss, irritation, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
Croatian: smanjenje broja crvenih krvnih stanica (koje može uzrokovati umor, nedostatak zraka, omaglicu), smanjenje broja neutrofila (zbog čega možete biti osjetljiviji na razne infekcije), smanjenje aktivnosti štitnjače (zbog čega se možete osjećati umorno, depresivno te biti osjetljiviji na hladnoću ili imati druge simptome), depresivnost ili razdražljivost, osjećaj mučnine u želucu, opće loše osjećanje, promjene raspoloženja, umor, poteškoće s uspavljivanjem ili održavanjem sna, virusna infekcija, slabost, proljev, omaglica, vrućica, simptomi nalik gripi, glavobolja, gubitak ili povećanje teka, gubitak težine, smanjenje brzine rasta (visina i težina), bol pod desnim rebrenim lukom, faringitis (upala grla), zimica i drhtavica, bol u trbuhu, povraćanje, suha koža, gubitak kose, iritacija, svrbež, bol u mišićima, bol u zglobovima i mišićima, osip.
English: Visual disturbance, blurred vision, conjunctivitis, eye irritation, eye pain, abnormal vision, lacrimal gland disorder, dry eye
Croatian: smetnje vida, zamagljen vid, konjunktivitis, iritacija oka, bol u oku, poremećaj vida, poremećaj suzne žlijezde, suho oko rijetko:
English: Current treatment guidelines should be consulted as to whether a liver biopsy is needed prior to commencing treatment.
Croatian: O nužnosti biopsije jetre prije početka liječenja mora se odlučiti na temelju važećih terapijskih smjernica.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Croatian: Od zdravstvenih djelatnika se traži da prijave svaku sumnju na nuspojavu lijeka na adresu Agencija za lijekove i medicinske proizvode (HALMED) Odsjek za farmakovigilanciju
English: Uncommonly reported side effects (may affect up to 1 in 100 people): abnormal behaviour, emotional disorder, fear, nightmare, bleeding of the mucous membrane that lines the inner surface of the eyelids, blurred vision, drowsiness, intolerance to light, itchy eyes, facial pain, inflamed gums, chest discomfort, difficult breathing, lung infection, nasal discomfort, pneumonia, wheezing, low blood pressure, enlarged liver, painful menstruation, itchy anal area (pinworms or ascarids), blistering rash (shingles), decreased sensitivity to touch, muscle twitching, pain in skin, paleness, peeling of skin, redness, swelling.
Croatian: Manje često prijavljene nuspojave (mogu se javiti u do 1 na 100 osoba): neuobičajeno ponašanje, emocionalni poremećaj, strah, noćne more, krvarenje iz sluznice koja oblaže unutarnju površinu kapaka, zamagljen vid, omamljenost, nepodnošenje svjetla, svrbež očiju, bol lica, upaljene desni, osjećaj nelagode u prsištu, otežano disanje, infekcija pluća, osjećaj nelagode u nosu, upala pluća, piskanje u plućima, nizak krvni tlak, povećana jetra,
English: SVR* SVR in patients with undetectable HCV-RNA at treatment week 12
Croatian: Nemjerljiva HCV-RNK u 12. tjednu liječenja
English: Previously treated patients - Retreatment of prior treatment failures (relapse and non-responder patients) with peginterferon alfa2b in combination with ribavirin:
Croatian: - Ponovljeno liječenje peginterferonom alfa-2b u kombinaciji s ribavirinom nakon neuspjeha prethodne terapije (bolesnici s relapsom i oni bez odgovora):
English: Table 4 Dosage Modification for Renal Impairment in Adult Patients Creatinine Clearance Ribavirin Mylan Dose (daily) 30 to 50 mL/min
Croatian: Tablica 4 Prilagodba doze za oštećenje funkcije bubrega u odraslih bolesnika Klirens kreatinina
English: Ribavirin 800-1,400 mg/day plus peginterferon alfa-2b 1.5 μg/kg once weekly
Croatian: Ribavirin Mylan (800 mg/dan) + peginterferon alfa-2b (1,5 µg/kg/ tjedan)
English: Also, refer to peginterferon alfa2b and interferon alfa-2b SmPCs for adverse reactions that may be attributable to interferons monotherapy.
Croatian: Međutim, peginterferon alfa-2b ili interferon alfa-2b koji se primjenjuju u kombinaciji s ribavirinom mogu imati učinak.
English: Wheezing, nasal discomfort Gastrointestinal disorders Very common:
Croatian: trombocitopenija, limfadenopatija Endokrini poremećaji vrlo često:
English: Dental and periodontal disorders: Dental and periodontal disorders, which may lead to loss of teeth, have been reported in patients receiving Ribavirin and peginterferon alfa-2b or interferon alfa-2b combination therapy.
Croatian: Poremećaji zuba i parodonta: U bolesnika koji su primali kombiniranu terapiju lijekom Ribavirin Mylan s peginterferonom alfa-2b ili interferonom alfa-2b prijavljene su bolesti zuba i parodonta koje mogu dovesti do gubitka zuba.
English: PSURs
Croatian: Nuspojave
English: coughing, inflamed gums, nose bleed, nose irritation, oral pain, pharyngitis (sore throat), rapid breathing, respiratory infections, scaling lips and clefts in the corners of the mouth, shortness of breath, sinusitis, sneezing, sores in mouth, sore tongue, stuffy or runny nose, throat pain, toothache, tooth abscess, tooth disorder, vertigo (spinning feeling), weakness chest pain, flushing, palpitations (pounding heart beat), rapid heart rate, abnormal liver function, acid reflux, back pain, bedwetting, constipation, gastroesophageal or rectal disorder, incontinence, increased appetite, inflammation of the membrane of the stomach and intestine, stomach upset, loose stools, urination disorders, urinary tract infection, difficult, irregular or no menstrual period, abnormally heavy and prolonged menstrual periods, disorder of vagina, inflammation of the vagina, testis pain, development of male body traits, acne, bruising, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), increased or decreased sensitivity to touch, increased sweating, increase in muscle movement, tense muscle, limb pain, nail disorder, numbness or tingling feeling, pale skin, rash with raised spotted lesions, shaky hands, redness of skin or skin disorder, skin discolouration, skin sensitive to sunlight, skin wound, swelling due to a build-up of excess water, swollen glands (swollen lymph nodes), tremor, tumour (unspecified).
Croatian: poremećaj jajnika ili rodnice, bol u dojkama, tegobe s erekcijom, promijenjena kvaliteta kose, akne, artritis, stvaranje modrica, ekcem (upaljena, crvena i suha koža koja svrbi, ponekad s ranicama iz kojih se cijedi tekući sadržaj), koprivnjača, pojačana ili smanjena osjetljivost na dodir, poremećaj nokti, grčevi mišića, osjećaj utrnutosti ili trnaca, bol u udovima, bol u zglobovima, drhtanje ruku, psorijaza, otečene ili nabrekle šake i nožni zglobovi, osjetljivost na sunčevu svjetlost, osip s mjestimičnim uzdignućima, crvenilo kože ili promjene na koži, otečeno lice, otečene žlijezde (otečeni limfni čvorovi), napetost mišića, tumor (nespecificiran), nesiguran hod, narušena ravnoteža vode u organizmu.
English: Plasma HCV -RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory *Intent to treat population includes 7 patients for whom at least 12 weeks of prior therapy could not be confirmed.
Croatian: * U skupinu s namjerom liječenja uključeno je i 7 bolesnika za koje se nije mogla potvrditi prethodna terapija u trajanju od najmanje 12 tjedana.
English: inflammation of pancreas, pain in bone, diabetes mellitus, muscle weakness.
Croatian: bol u kostima, mišićna slabost rijetko:
English: Cardiac disorders Common:
Croatian: infarkt miokarda rijetko:
English: Ribavirin in combination with peginterferon alfa-2b Multiple-dose pharmacokinetic properties for ribavirin and peginterferon alfa-2b in children and adolescent patients with chronic hepatitis C have been evaluated during a clinical study.
Croatian: U kliničkom ispitivanju u djece i adolescenata s kroničnim hepatitisom C procijenjena su farmakokinetička svojstva ponovljene doze ribavirina i peginterferona alfa-2b nakon višestrukih doza.
English: Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord), bronchoconstriction and anaphylaxis (a severe, whole-body allergic reaction), constant cough, eye problems including damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye and cotton wool spots (white deposits on the retina), enlarged abdominal area, heartburn, trouble having bowel movement or painful bowel movement,
Croatian: Kada se ovaj lijek uzimao u kombinaciji s alfa interferonom, prijavljene su i ove druge nuspojave: neuobičajene misli, opažanje zvukova ili slika koji nisu stvarni, promjena psihičkog stanja, dezorijentiranost, angioedem (oticanje šaka, stopala, nožnih zglobova, lica, usana, usta ili grla, što može uzrokovati poteškoće pri gutanju ili disanju), sindrom Vogt-Koyanagi-Harada (autoimuni upalni poremećaj koji zahvaća oči, kožu te ušne, moždane i ovojnice kralježnične moždine), bronhokonstrikcija i anafilaksija (teška alergijska reakcija cijelog organizma), uporan kašalj, tegobe s očima koje uključuju oštećenje mrežnice, opstrukciju mrežnične arterije, upalu očnog živca, oticanje oka i pamučasta krvarenja u mrežnici (bijele nakupine na mrežnici), povećan trbuh, žgaravica, poteškoće kod pražnjenja crijeva ili bolno pražnjenje crijeva, akutne reakcije preosjetljivosti uključujući urtikariju (koprivnjaču), stvaranje modrica, jaka bol u udovima, bol u nozi ili bedru, smanjen opseg pokreta, ukočenost, sarkoidoza (bolest koju prati stalna vrućica, gubitak tjelesne težine, bol i oticanje zglobova, oštećenja kože i oticanje limfnih čvorova).
English: Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation, or suicide attempt.
Croatian: Djeca i adolescenti: - postojeći ili u anamnezi zabilježen teški psihijatrijski poremećaj, osobito teška depresija,
English: Reminder: Please read the “Other medicines” section of the Package Leaflet for interferon alfa-2b before you begin combination treatment with this medicine.
Croatian: Podsjetnik: Prije nego započnete liječenje kombinacijom s ovim lijekom, molimo pročitajte i dio „Drugi lijekovi” ove Upute o lijeku za interferon alfa-2b..
English: Pain in extremity, back pain, muscle contracture Renal and urinary disorders Common:
Croatian: bol u ekstremitetima, bol u leđima, kontrakture mišića
English: acute hypersensitivity reactions including urticaria (hives), bruises, intense pain in a limb, leg or thigh pain, loss of range of motion, stiffness, sarcoidosis, (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands).
Croatian: bolne mjesečnice, svrbež analnog područja (dječje gliste ili askaridi), mjehurićasti pojasasti osip (herpes zoster), smanjena osjetljivost na dodir, trzanje mišića, bol u koži, bljedilo, ljuštenje kože, crvenilo, oticanje.
English: tel: + 34 900 102 712
Croatian: Mylan Pharmaceuticals, S.L. tel: + 34 900 102 712
English: Table 15
Croatian: 13. BROJ SERIJE
English: No paediatric subjects with SVR relapsed during the 5 years of follow-up.
Croatian: Tijekom 5 godina praćenja ni u jednog pedijatrijskog bolesnika s trajnim virološkim odgovorom nije došlo do relapsa
English: Each capsule contains 200 mg ribavirin.
Croatian: - Djelatna tvar je ribavirin 200 mg.
English: • Grounds for refusal
Croatian: • Razlozi za odbijanje
English: At individual level the variability between patients is evident and separation between groups is not so clear.
Croatian: Na pojedinačnoj razini varijabilnost među bolesnicima je očita, a razdvajanje među skupinama nije toliko jasno.
English: The applicant requested a Conditional marketing authorisation based on their claim that their application fulfils all the requirements from in Regulation (EC) No 507/2006.
Croatian: Podnositelj zahtjeva zatražio je Uvjetno odobrenje za stavljanje u promet na temelju svoje tvrdnje da njegov zahtjev ispunjava sve kriterije iz Uredbe (EZ) br. 507/2006.
English: The CHMP is of the opinion that pursuant to Article 12 of Regulation (EC) No 726/2004, the efficacy and the safety of the above mentioned medicinal product is not properly or sufficiently demonstrated.
Croatian: CHMP je mišljenja da, u skladu s člankom 12. Uredbe (EZ) br. 726/2004, djelotvornost i sigurnost prethodno navedenog lijeka nisu ispravno ili dostatno dokazane.
English: Annex Scientific conclusions and grounds for refusal presented by the European Medicines Agency
Croatian: Prilog Znanstveni zaključci i razlozi za odbijanje koje je iznijela Europska agencija za lijekove
English: This is even more relevant when the external controls are retrospectively selected.
Croatian: To je još relevantnije kada se vanjske kontrolne skupine odabiru retroaktivno.
English: Regarding the laboratory findings the main concern is proteinuria that has already been observed in nonclinical studies.
Croatian: Što se tiče laboratorijskih rezultata, glavni izvor zabrinutosti jest proteinurija, koja je već uočena u nekliničkim ispitivanjima.
English: Overall summary of the scientific evaluation of Exondys after re-examination
Croatian: Cjelokupni sažetak znanstvene ocjene lijeka Exondys nakon ponovne procjene
English: The lack of a placebo controlled arm prevent from drawing any conclusions.
Croatian: Nedostatak skupine kontrolirane placebom sprječava donošenje zaključaka.
English: Separation between curves is apparent at Year 3 (Year 3 - 144 metres, p=0.0055; Year 4 - 161 metres, p=0.0007).
Croatian: Razdvajanje među krivuljama očito je u 3. godini (3. godina - 144 metra, p=0,0055; 4. godina - 161 metar, p=0,0007).
English: The limitation derived from the small numbers is acknowledged, but the fact that it is a result of the small number of patients does not reduce the uncertainty related to the results observed.
Croatian: Uzeto je u obzir ograničenje koje nastaje zbog malih brojeva, ali činjenica da je to rezultat malog broja bolesnika ne smanjuje nesigurnost povezanu s uočenim rezultatima.
English: Without an appropriate concurrent control it is not possible to conclude that the results are reflecting a true and clinically meaningful change (slowing the progression) in the course of the condition.
Croatian: Bez prikladne istovremene kontrole nije moguće zaključiti upućuju li rezultati na stvarnu i klinički značajnu promjenu (usporavanje napretka bolesti) tijekom stanja.
English: Therefore, safety data have to be interpreted with caution, precluding any firm conclusions on the safety profile of the product.
Croatian: Prema tome, podatci o sigurnosti moraju se oprezno tumačiti, bez donošenja čvrstih zaključaka o sigurnosnom profilu lijeka.
English: During the initial CHMP assessment, three additional clinical studies were being conducted, in order to provide additional data to support the application.
Croatian: Tijekom ocjenjivanja CHMP-a provodila su se tri dodatna klinička ispitivanja kako bi se dobili dodatni podatci kao potpora zahtjevu.
English: The Applicant has defined post-hoc several external controls that have been used for different comparisons.
Croatian: Podnositelj zahtjeva naknadno je definirao nekoliko vanjskih kontrolnih skupina koje su upotrijebljene za različite usporedbe.
English: As the minimum amount of truncated dystrophin expression that is needed to achieve a clinically relevant benefit remains unknown, the value of these data is mainly to serve as supportive for the proposed mechanism of action of the product.
Croatian: Budući da je minimalna količina ekspresije skraćenog distrofina potrebna za postizanje klinički relevantne koristi i dalje nepoznata, vrijednost tih podataka ponajprije se odnosi na to da služe kao potpora za predloženi mehanizam djelovanja proizvoda.
English: The comparison with external control cohort from natural history databases presents with methodological deficiencies, and its results can only be considered as exploratory or supportive.
Croatian: Usporedba s vanjskom kontrolnom skupinom iz baza podataka o prirodnom tijeku bolesti ima metodološke manjkavosti, a njezini rezultati mogu se smatrati samo eksplorativnima ili pomoćnima.
English: At time of Opinion, there are no outstanding issues on the quality of the active substance or the medicinal product.
Croatian: U trenutku donošenja mišljenja nisu postojala neriješena pitanja u pogledu kvalitete djelatne tvari ili lijeka.
English: • Efficacy of eteplirsen remains not demonstrated.
Croatian: • Djelotvornost lijeka eteplirsen i dalje nije dokazana.
English: Therefore, the CHMP has recommended the refusal of the granting of the conditional marketing authorisation for Exondys.
Croatian: Stoga je CHMP preporučio odbijanje izdavanja uvjetnog odobrenja za stavljanje lijeka Exondys u promet.
English: The additional data provided from the open-label phase, a 4-year period of treatment, do not allow to convincingly conclude on a relevant effect of eteplirsen in this population.
Croatian: Dodatni podatci dobiveni u otvorenoj fazi, 4-godišnjem razdoblju liječenja, ne omogućuju donošenje pouzdanog zaključka o relevantnom učinku lijeka eteplirsen u ovoj populaciji.
English: • The provided additional comparative data from a variety of external controls, derived from different studies and populations, suffer from important limitations related to the nature of the methodology used (non-concurrent, retrospectively selected, post-hoc defined).
Croatian: • Dostavljeni dodatni komparativni podatci iz različitih vanjskih kontrolnih skupina, dobiveni iz različitih ispitivanja i populacija, imaju značajna ograničenja povezana s primijenjenom metodologijom (nekonkurentna, retroaktivno odabrana, naknadno definirana).
English: However, the CHMP concluded that the medicinal product did not fulfil all of the criteria set out in Article 4(1) of the Regulation, such as, the current benefit-risk balance could not be considered positive based on the available, submitted data.
Croatian: Međutim, CHMP je zaključio da lijek ne ispunjava sve kriterije utvrđene u članku 4. stavku 1. Uredbe, jer se, na primjer, trenutačni omjer koristi i rizika ne može smatrati pozitivnim na temelju dostupnih i podnesenih podataka.
English: The potential sources of bias, using this strategy, seriously affect the reliability of the subsets and comparisons, and the conclusions made thereof.
Croatian: Potencijalni izvori pristranosti pri primjeni te strategije ozbiljno utječu na pouzdanost podskupova i usporedbi te zaključaka donesenih na temelju navedenoga.
English: This increases the uncertainty about the reliability of such comparisons rather than providing confirmatory data for efficacy.
Croatian: Time se povećava nesigurnost u pogledu pouzdanosti takvih usporedbi, a ne dobivaju se podatci koji potvrđuju djelotvornost.
English: In terms of the pharmacodynamic proof of concept, a modest increase in dystrophin (truncated) production has been shown in some patients, while in a number of them no production was detected.
Croatian: U smislu farmakodinamičkog dokaza koncepta, u nekih je bolesnika uočeno blago povećanje proizvodnje distrofina (skraćenog), dok u brojnih bolesnika nije uočena nikakva proizvodnja.
English: This small and acquired in a non-comparative manner, dataset makes the assessment of the long-term safety impossible.
Croatian: Ovaj mali skup podataka stečen bez usporedbe čini ocjenjivanje dugoročne sigurnosti lijeka nemogućim.
English: There was no difference in 6MWD between eteplirsen and placebo during this 24 week treatment period.
Croatian: Nije uočena razlika u 6MWD između lijeka eteplirsen i placeba tijekom tog 24-tjednog razdoblja liječenja.
English: In general, this strategy increases the uncertainty about the results rather than providing reassuring comparisons.
Croatian: Općenito govoreći, ovom strategijom povećava se nesigurnost u pogledu rezultata i ne pružaju se uvjerljive usporedbe.